Castle Biosciences公司旗下DecisionDx®-黑色素瘤检测的最新突破性研究引发行业关注。该领域迄今规模最大的前瞻性多中心临床试验数据显示，通过基因表达谱测试被判定为淋巴结转移风险低于5%的黑色素瘤患者群体，实际淋巴结阳性率稳定控制在2.6%水平。这一关键验证不仅显著强化了该检测技术在临床决策支持系统中的可靠性，更为皮肤科医生制定精准化手术方案提供了重要循证依据。
Castle Biosciences公司旗下DecisionDx®-黑色素瘤检测的最新突破性研究引发行业关注。该领域迄今规模最大的前瞻性多中心临床试验数据显示，通过基因表达谱测试被判定为淋巴结转移风险低于5%的黑色素瘤患者群体，实际淋巴结阳性率稳定控制在2.6%水平。这一关键验证不仅显著强化了该检测技术在临床决策支持系统中的可靠性，更为皮肤科医生制定精准化手术方案提供了重要循证依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.